Standardization

Pharmacological activity

RICE GERM (Oryza Sativa)

• Source of GABA;
• Plays an inhibiting role in the stress appearance mechanism;
• Mental and physical tranquillizer;
• Restores the quality of sleep.

BACOPA (Bacopa Monnieri)

• Improves cognitive faculties;
• Increases concentration;
• Facilitates memorizing.

MUCUMA (Mucuma Pruriens)

• Central nervous system tonic;
• Dopamine precursor;
• L-Dopa supplier;
• Increases concentration.

PHOSPHATYDILSERINE

• Reinforces cognitive functions;
• Facilitates memorizing;
• Increases concentration.

PREGNENOLONE

• Stimulates the central nervous system activity;
• Increases memorization capacity;
• Decreases stress.

• Regular use: Take 1½ teaspoon (7,5 ml) daily. For an adult, if the effect is insufficient after 2 weeks, the posology may be doubled.

• Attention deficit (children and adults);
• Learning disabilities and hyperactivity disorders;
• Memory disturbances or weak memory capacity;
• Stress and nervousness.

CONTRAINDICATIONS

• Avoid using in case of allergy to the ingredients in the present formulation;
• Avoid giving to pregnant and breastfeeding women;
• Avoid consuming with alcohol.
• In the event of serious disease or consumption with other medications, do not take this product without the consent of an expert healthcare professional.

PRECAUTIONS

• People with bipolar type disorders, severe depression, schizophrenia and epilepsy or before combining with any other product or medication;
• Hepatic or cardiovascular dysfunctions, psychiatric disorders, skin cancer (melanoma), diabetes and ulcer;
• Cease the use and consult a health practitioner if the symptoms persist or if undesirable effects should occur.

MEDICINAL INTERACTIONS

• MAOI;
• Anticoagulants;
• Antipsychotic, lithium and neuroleptics;
• Hypoglycemic medications;
• Anesthetic medicines;
• Derivatives from amphetamines (Ritalin, etc.);
• Alcohol;

SIDE EFFECTS

• If the product is consumed in much higher quantities than the prescribed posology, the following side effects may occur: nausea, dryness of the mouth, tiredness, sedation, anxiety, irritability, insomnia, headaches and gastrointestinal discomforts.

SPEED OF THE EFFECTS

• Although an immediate calming effect is usually noted, it however takes a little time to notice improvements in concentration, attention and memory. Normally, it is possible to observe a great improvement in concentration and hyperactivity in two weeks;
• It will take a few months before the brain can recover a new level of neurotransmitter activity. In order to obtain a lasting effect and be able to cease taking the product without losing the acquired improvements, the person will need to take Focus for at least a year.

SYNERGISTIC ACTION

• Focus has an impact on concentration, hyperactivity and attention deficit. The problems of people suffering of ADD/ADHD are connected to an unstable activity of the neurotransmitters. This formulation acts on distinct neurotransmitters in order to obtain a greater effect. It is necessary to regulate the secretion and to recover dopamine, GABA, noradrenalin and other secondary neurotransmitters. By doing this, the improvement will be durable and without side effects such as depression, nervousness, etc.

• Mucuma, bacopa and phosphatidylcholine are excellent to increase concentration and dopamine levels in the brain. They are used for diseases of the nervous system, hyperactivity, attention deficit disorder and hydropisy (generalized edema). Rice germs have an impact on GABA by regulating the level of this neurotransmitter. They have the capacity to decrease anxiety and increase mental function.
• Pregnenolone is a neuro-steroidal hormone implied in synaptic transmission and myelin formulation. It improves cognitive functions and memorizing capacity.

• Akwa Y, Young J, Kabbadj K, et al. Neurosteroids: biosynthesis, metabolism and function of pregnenolone and dehydroepiandrosterone in the brain. J Steroid Biochem Molec Biol 1991; 40(1–3):71–81.
• Flood JF, Morley JE, Roberts E. Memory-enhancing effects in male mice of pregnenolone and steroids metabolically derived from it. Proc Natl Acad Sci 1992;89:1567–71.
• Flood JF, Morley JE, Roberts E. Pregnenolone sulfate enhances post-training memory processes when injected in very low doses into limbic system structures: the amygdala is by far the most sensitive. Proc Natl Acad Sci 1995;92:10806–10.
• George MS, Guidotti A, Rubinow D, et al. CSF neuroactive steroids in affective disorders: pregnenolone, progesterone and DBI. Biol Psychiatry 1994;35:775–80.
• Guth L, Zhang Z, Roberts E. Key role for pregnenolone in combination therapy that promotes recovery after spinal cord injury. Proc Natl Acad Sci 1994;91:12308–12.
• Isaacson RL, Varner JA, Baars JM, de Wied D. The effects of pregnenolone sulfate and ethylestrenol on retention of a passive avoidance task. Brain Res 1995;689:79–84.
• Maione S, Berrino L, Vitagliano S, et al. Pregnenolone sulfate increases the convulsant potency of N-methyl-D-aspartate in mice. Eur J Pharmacol 1992;219:477–9.
• McGavack TH, Chevalley J, Weissberg J. The use of D 5-pregnenolone in various clinical disorders. J Clin Endocrinol 1951;11:559–77.
• Melchior CL, Ritzmann RF. Pregnenolone and pregnenolone sulfate, alone and with ethanol, in mice on the plus-maze. Pharmacol Biochem Behav 1994;48:893–7.
• Morfin R, Young J, Corpechot C, et al. Neurosteroids: pregnenolone in human sciatic nerves. Proc Natl Acad Sci 1992;89:6790–3.
• Pincus G, Hoagland H. Effects of administered pregnenolone on fatiguing psychomotor performance. Aviation Med 1944;April:98–115.
• Steiger A, Trachsel L, Guldner J, et al. Neurosteroid pregnenolone induces sleep-EEG changes in man compatible with inverse agonistic GABAreceptor modulation. Brain Res 1993;615:267–74.
• Sternberg TH, LeVan P, Wright ET. The hydrating effects of pregnenolone acetate on the human skin. Curr Ther Res 1961;3:469–71.
• Vallee M, Mayo W, Le Moal M. Role of pregnenolone, dehydroepiandrosterone and their sulfate esters on learning and memory in cognitive aging. Brain Res Rev. 2001 Nov;37(1-3):301.
• Wu FS, Gibbs TT, Farb DH. Pregnenolone sulfate: a positive allosteric modulator at the N-methyl-D-aspartate receptor. Mol Pharmacol 1991;40:333–6.
• Kidd PM. A review of nutrients and botanicals in the integrative management of cognitive dysfunction. Altern Med Rev. 1999 Jun;4 http://www.thorne.com
• Stough C, Lloyd J, Clarke J, Downey LA, Hutchison CW, Rodgers T, Nathan PJ. The chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjects.Psychopharmacology (Berl). 2001 Aug;156(4):481-4.
• Manyam Bala V. Beans (Mucuna Pruriens) For Parkinson's Disease: An Herbal Alternative. National Parkinson Foundation http://www.parkinson.org
• HP-200 in Parkinson's Disease Study Group. An alternative medicine treatment for Parkinson's disease: results of a multicenter clinical trial.J Altern Complement Med. 1995 Fall; 1(3): 249-55.
• Nagashayana N, Sankarankutty P, Nampoothiri MR, Mohan PK, Mohanakumar KP. Association of L-DOPA with recovery following Ayurveda medication in Parkinson's disease.J Neurol Sci. 2000 Jun 15; 176(2): 124-7.
• Jorissen BL, Brouns F, Van Boxtel MP, Ponds RW, Verhey FR, Jolles J, Riedel WJ. The influence of soy-derived phosphatidylserine on cognition in age-associated memory. impairment.Nutr Neurosci. 2001;4(2):121-34.
• Cenacchi T, Bertoldin T, Farina C, Fiori MG, Crepaldi G. Cognitive decline in the elderly: a double-blind, placebo-controlled multicenter study on efficacy of phosphatidylserine administration.Aging (Milano). 1993 Apr;5(2):123-33.
• Crook TH, Tinklenberg J, Yesavage J, Petrie W, Nunzi MG, Massari DC. Effects of phosphatidylserine in age-associated memory impairment.Neurology. 1991 May;41(5):644-9.
• Jumpsen JA, Lien EL, Goh YK, Clandinin MT. During neuronal and glial cell development diet n - 6 to n - 3 fatty acid ratio alters the fatty acid composition of phosphatidylinositol and phosphatidylserine. Biochim Biophys Acta. 1997 Jul 12;1347(1):40-50.
• Monteleone P, Beinat L, Tanzillo C, Maj M, Kemali D. Effects of phosphatidylserine on the neuroendocrine response to physical stress in humans. Neuroendocrinology. 1990 Sep;52(3):243-8.
• Monteleone P, Maj M, Beinat L, Natale M, Kemali D. Blunting by chronic phosphatidylserine administration of the stress-induced activation of the hypothalamo-pituitary-adrenal axis in healthy men. Eur J Clin Pharmacol. 1992;42(4):385-8.
• Goodman and Gilman’s, the pharmacological basic of therapeutics, seventh edition, 1985, Amino-acid P.247-250; 487.
• Serrano A, Haddjeri N, Lacaille JC' Robitaille R. GABAergic network activation of glial cells Underlies hippocampal heterosynaptic depression. J Neurosci. 2006 May 17;26(20):5370-82.
• American Psychiatric association, DSM-IV, Manuel diagnostique et statistique des troubles mentaux. Traduction française, Paris, Masson, 1996, 1056p.
• Diboune M, Ferard G, Ingenbleek Y, Bourguignat A, Spielmann D, Scheppler-Roupert C, Tulasne PA, Calon B, Hasselmann M, Sauder P, et al.
• Soybean oil, blackcurrant seed oil, medium-chain triglycerides, and plasma phospholipid fatty acids of stressed patients. Nutrition. 1993 Jul-Aug;9(4):344-9.
• DiPalma JR. Nutritional pharmacology. Am Fam Physician. 1985 Aug;32(2):171-3.
• Farquharson J, Jamieson EC, Abbasi KA, Patrick WJ, Logan RW, Cockburn F. Effect of diet on the fatty acid composition of the major phospholipids of infant cerebral cortex. Arch Dis Child. 1995 Mar;72(3):198-203.
• Fenton WS, Hibbeln J, Knable M. Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia. Biol Psychiatry. 2000 Jan 1;47(1):8-21.
• Growdon JH, Wurtman RJ. Dietary influences on the synthesis of neurotransmitters in the brain. Nutr Rev. 1979 May;37(5):129-36.
• Hals J, Bjerve KS, Nilsen H, Svalastog AG, Ek J. Essential fatty acids in the nutrition of severely neurologically disabled children. Br J Nutr. 2000 Mar;83(3):219-25.
• Jamieson EC, Abbasi KA, Cockburn F, Farquharson J, Logan RW, Patrick WA. Effect of diet on term infant cerebral cortex fatty acid composition. World Rev Nutr Diet. 1994;75:139-41.
• Kelly GS. Nutritional and botanical interventions to assist with the adaptation to stress. Altern Med Rev. 1999 Aug;4(4):249-65.
• Khalsa DS. Integrated medicine and the prevention and reversal of memory loss. Altern Ther Health Med. 1998 Nov;4(6):38-43.
• Kohn G, Sawatzki G, van Biervliet JP, Rosseneu M. Diet and the essential fatty acid status of term infants. Acta Paediatr Suppl. 1994 Sep;402:69-74.
• Leathwood PD. Neurotransmitter precursors and brain function. Bibl Nutr Dieta. 1986;(38):54-71.
• Lutz M. Diet as a determinant of central nervous system development: role of essential fatty acids. Arch Latinoam Nutr. 1998 Mar;48(1):29-34.
• Mahadik SP, Mukherjee S, Horrobin DF, Jenkins K, Correnti EE, Scheffer RE. Plasma membrane phospholipid fatty acid composition of cultured skin fibroblasts from schizophrenic patients: comparison with bipolar patients and normal subjects. Psychiatry Res. 1996 Jul 31;63(2-3):133-42.
• Newman PE. Could diet be one of the causal factors of Alzheimer's disease? Med Hypotheses. 1992 Oct;39(2):123-6.
• Pasquale J. Accardo and Jennifer A. Accardo, Say no to Drugs?, The Journal of Pediatrics, Volume 147, Issue 3, September 2005, Pages 286-287.
• Rosenberg GS, Davis KL. Precursors of acetylcholine: considerations underlying their use in Tourette syndrome. Adv Neurol. 1982;35:407-12.
• RYSER CA, KIDD PM. Benefits of PS (phosphatidylserine) against attention deficit in a preliminary study. Lancet (Letter, in preparation).
• SCHARDT D. Diet and behavior in children, Nutrition action Healthletter 2000;27:10-11. Washington, DC: Center for Science in the Public Interest.
• Sato N, Murakami Y, Nakano T, Sugawara M, Kawakami H, Idota T, Nakajima I. Effects of dietary nucleotides on lipid metabolism and learning ability of rats. Biosci Biotechnol Biochem. 1995 Jul;59(7):1267-71.
• Wurtman RJ. Nutrients that modify brain function. Sci Am. 1982 Apr;246(4):50-9.